QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.005017v1 33/12/1886    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saulter, J. Y. Articles by Hall, J. E. Search for Related Content PubMed PubMed Citation Articles by Saulter, J. Y. Articles by Hall, J. E.

UNUSUAL DEHYDROXYLATION OF ANTIMICROBIAL AMIDOXIME PRODRUGS BY CYTOCHROME b₅ AND NADH CYTOCHROME b₅ REDUCTASE

School of Pharmacy, the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.Y.S., R.R.T., A.S.B., J.E.H.); Medical Sciences, The University of Wisconsin-Madison, Madison, Wisconsin (J.R.K., L.A.T.); and Department of Chemistry, Georgia State University, Atlanta, Georgia (D.W.B., C.E.S., M.A.)

Furamidine is an effective antimicrobial agent; however, oral potency of furamidine is poor. A prodrug of furamidine, 2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime (DB289), has greatly improved oral potency. DB289 is transformed to furamidine via O-demethylation, and N-dehydroxylation reactions with four intermediate metabolites formed. The O-demethylation reactions have been shown to be catalyzed by cytochrome P450. The enzymes catalyzing the reductive N-dehydroxylation reactions have not been determined. The objective of this study was to identify the enzymes that catalyze N-dehydroxylation of metabolites M1, a monoamidoxime, and M2, a diamidoxime, formed during generation of furamidine. M1 and M2 metabolism was investigated using human liver microsomes and human soluble cytochrome b₅ and NAD cytochrome b₅ reductase, expressed in Escherichia coli. Kinetics of M1 and M2 reduction by human liver microsomes exhibited high affinity and moderate capacity. Metabolism was significantly inhibited by antibodies to cytochrome b₅ and b₅ reductase and by chemical inhibitors of b₅ reductase. The amidoximes were efficiently metabolized by liver mitochondria, which contain cytochrome b₅/b₅ reductase, but not by liver cytosol, which contains minimal amounts of these proteins. Expressed cytochrome b₅/b₅ reductase, in the absence of any other proteins, efficiently catalyzed reduction of both amidoximes. K_m values were similar to those for microsomes, and V_max values were 33- to 36-fold higher in the recombinant system compared with microsomes. Minimal activity was seen with cytochrome b₅ or b₅ reductase alone or with cytochrome P450 reductase alone or with cytochrome b₅. These results indicate that cytochrome b₅ and b₅ reductase play a direct role in metabolic activation of DB289 to furamidine.

This article has been cited by other articles:

				M. M. Nyunt, C. W. Hendrix, R. P. Bakshi, N. Kumar, and T. A. Shapiro Phase I/II Evaluation of the Prophylactic Antimalarial Activity of Pafuramidine in Healthy Volunteers Challenged with Plasmodium falciparum Sporozoites Am J Trop Med Hyg, April 1, 2009; 80(4): 528 - 535. [Abstract] [Full Text] [PDF]

				M. Z. Wang, J. Q. Wu, A. S. Bridges, D. C. Zeldin, S. Kornbluth, R. R. Tidwell, J. E. Hall, and M. F. Paine Human Enteric Microsomal CYP4F Enzymes O-Demethylate the Antiparasitic Prodrug Pafuramidine Drug Metab. Dispos., November 1, 2007; 35(11): 2067 - 2075. [Abstract] [Full Text] [PDF]

				M. Z. Wang, J. Y. Saulter, E. Usuki, Y.-L. Cheung, M. Hall, A. S. Bridges, G. Loewen, O. T. Parkinson, C. E. Stephens, J. L. Allen, et al. CYP4F Enzymes Are the Major Enzymes in Human Liver Microsomes That Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289 [2,5-Bis(4-amidinophenyl)furan-bis-O-methylamidoxime] Drug Metab. Dispos., December 1, 2006; 34(12): 1985 - 1994. [Abstract] [Full Text] [PDF]